Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development

Table 4 Risk factors and genetic polymorphisms associated with OIPN

OIPN	Comments	Reference
Risk factors associated with OIPN	Age; comorbid health conditions: decreased creatinine clearance, smoking, etc.; raised BMI; low serum albumin; and baseline neuropathy	[2, 4, 41]
	Medication: cardiovascular especially beta blockers; use of opioids	[42, 43]
	Quantitative sensory testing deficits in patients	[38, 39]
	Thermal hyperalgesia	[40]
	Neurofilament light chains in plasma or serum samples	[36, 37]
Genetic polymorphisms associated with OIPN	GSTP1 gene (Ile105Val polymorphism), cytochrome P450 enzymes, OCT2, ABCC2, and AGXT	[44,45,46,47,48,49,50].
	SCN4A (rs2302237); SCN10A (rs1263292) associated with an increased incidence of acute oxaliplatin-induced CIPN	[51]
	SCN9A (rs6746030) protected against severe oxaliplatin-induced CIPN	[52]

ABCC2 ATP binding cassette subfamily C member 2, AGXT Alanine glyoxylate aminotransferase, BMI Body mass index, CIPN Chemotherapy-induced peripheral neuropathy, GSTP1 Glutathione S-transferase pi 1, OCT2 Organic cation transporter 2, OIPN Oxaliplatin-induced peripheral neuropathy, SCN10A Sodium channel protein type 10 subunit alpha, SCN4A Sodium channel protein type 4 subunit alpha, SCN9A Sodium channel protein type 9 subunit alpha

ISSN: 1756-9966